vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and SENSIENT TECHNOLOGIES CORP (SXT). Click either name above to swap in a different company.

CLOVER HEALTH INVESTMENTS, CORP. is the larger business by last-quarter revenue ($487.7M vs $435.8M, roughly 1.1× SENSIENT TECHNOLOGIES CORP). SENSIENT TECHNOLOGIES CORP runs the higher net margin — 10.1% vs -10.1%, a 20.2% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs 11.1%). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (18.6% CAGR vs 3.9%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

Sensient Technologies is a global manufacturer and marketer of colors, flavors and fragrances based in Milwaukee, Wisconsin. Their products are used in many foods and beverages, pharmaceuticals, cosmetics, home and personal care products, specialty printing and imaging products, computer imaging and industrial colors. Sensient reported revenue of $1,468 million in 2013. Subdivisions include the Sensient Flavors & Fragrances Group and the Sensient Color Group. Within the Flavors & Fragrances G...

CLOV vs SXT — Head-to-Head

Bigger by revenue
CLOV
CLOV
1.1× larger
CLOV
$487.7M
$435.8M
SXT
Growing faster (revenue YoY)
CLOV
CLOV
+33.6% gap
CLOV
44.7%
11.1%
SXT
Higher net margin
SXT
SXT
20.2% more per $
SXT
10.1%
-10.1%
CLOV
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
18.6%
3.9%
SXT

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CLOV
CLOV
SXT
SXT
Revenue
$487.7M
$435.8M
Net Profit
$-49.3M
$44.2M
Gross Margin
Operating Margin
-10.1%
15.3%
Net Margin
-10.1%
10.1%
Revenue YoY
44.7%
11.1%
Net Profit YoY
-123.2%
28.2%
EPS (diluted)
$1.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
SXT
SXT
Q1 26
$435.8M
Q4 25
$487.7M
$393.4M
Q3 25
$496.6M
$412.1M
Q2 25
$477.6M
$414.2M
Q1 25
$462.3M
$392.3M
Q4 24
$337.0M
$376.4M
Q3 24
$331.0M
$392.6M
Q2 24
$356.3M
$403.5M
Net Profit
CLOV
CLOV
SXT
SXT
Q1 26
$44.2M
Q4 25
$-49.3M
$25.5M
Q3 25
$-24.4M
$37.0M
Q2 25
$-10.6M
$37.6M
Q1 25
$-1.3M
$34.5M
Q4 24
$-22.1M
$30.1M
Q3 24
$-9.2M
$32.7M
Q2 24
$7.4M
$30.9M
Gross Margin
CLOV
CLOV
SXT
SXT
Q1 26
Q4 25
31.4%
Q3 25
34.3%
Q2 25
34.5%
Q1 25
33.6%
Q4 24
31.7%
Q3 24
24.5%
33.2%
Q2 24
30.3%
32.4%
Operating Margin
CLOV
CLOV
SXT
SXT
Q1 26
15.3%
Q4 25
-10.1%
9.7%
Q3 25
-4.9%
14.0%
Q2 25
-2.2%
13.9%
Q1 25
-0.3%
13.6%
Q4 24
-6.4%
11.2%
Q3 24
-2.7%
12.9%
Q2 24
2.0%
12.3%
Net Margin
CLOV
CLOV
SXT
SXT
Q1 26
10.1%
Q4 25
-10.1%
6.5%
Q3 25
-4.9%
9.0%
Q2 25
-2.2%
9.1%
Q1 25
-0.3%
8.8%
Q4 24
-6.6%
8.0%
Q3 24
-2.8%
8.3%
Q2 24
2.1%
7.7%
EPS (diluted)
CLOV
CLOV
SXT
SXT
Q1 26
$1.04
Q4 25
$0.60
Q3 25
$0.87
Q2 25
$0.88
Q1 25
$0.81
Q4 24
$0.71
Q3 24
$0.77
Q2 24
$0.73

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
SXT
SXT
Cash + ST InvestmentsLiquidity on hand
$78.3M
$38.5M
Total DebtLower is stronger
$767.8M
Stockholders' EquityBook value
$308.7M
$1.2B
Total Assets
$541.0M
$2.3B
Debt / EquityLower = less leverage
0.63×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
SXT
SXT
Q1 26
$38.5M
Q4 25
$78.3M
$36.5M
Q3 25
$42.7M
Q2 25
$56.7M
Q1 25
$32.6M
Q4 24
$194.5M
$26.6M
Q3 24
$288.0M
$37.0M
Q2 24
$254.8M
$30.3M
Total Debt
CLOV
CLOV
SXT
SXT
Q1 26
$767.8M
Q4 25
$709.2M
Q3 25
Q2 25
Q1 25
Q4 24
$613.5M
Q3 24
Q2 24
Stockholders' Equity
CLOV
CLOV
SXT
SXT
Q1 26
$1.2B
Q4 25
$308.7M
$1.2B
Q3 25
$340.9M
$1.2B
Q2 25
$344.2M
$1.2B
Q1 25
$336.1M
$1.1B
Q4 24
$341.1M
$1.1B
Q3 24
$342.2M
$1.1B
Q2 24
$324.9M
$1.1B
Total Assets
CLOV
CLOV
SXT
SXT
Q1 26
$2.3B
Q4 25
$541.0M
$2.2B
Q3 25
$559.7M
$2.2B
Q2 25
$575.0M
$2.2B
Q1 25
$583.7M
$2.1B
Q4 24
$580.7M
$2.0B
Q3 24
$653.0M
$2.0B
Q2 24
$674.2M
$2.0B
Debt / Equity
CLOV
CLOV
SXT
SXT
Q1 26
0.63×
Q4 25
0.59×
Q3 25
Q2 25
Q1 25
Q4 24
0.58×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
SXT
SXT
Operating Cash FlowLast quarter
$-66.9M
Free Cash FlowOCF − Capex
$-69.0M
FCF MarginFCF / Revenue
-14.1%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-69.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
SXT
SXT
Q1 26
Q4 25
$-66.9M
$44.6M
Q3 25
$12.1M
$44.0M
Q2 25
$5.4M
$48.3M
Q1 25
$-16.3M
$-9.0M
Q4 24
$34.8M
$21.4M
Q3 24
$50.0M
$76.8M
Q2 24
$44.8M
$43.8M
Free Cash Flow
CLOV
CLOV
SXT
SXT
Q1 26
Q4 25
$-69.0M
$12.9M
Q3 25
$11.4M
$24.2M
Q2 25
$4.8M
$27.1M
Q1 25
$-16.5M
$-25.8M
Q4 24
$33.3M
$-1.7M
Q3 24
$49.6M
$63.6M
Q2 24
$44.4M
$32.0M
FCF Margin
CLOV
CLOV
SXT
SXT
Q1 26
Q4 25
-14.1%
3.3%
Q3 25
2.3%
5.9%
Q2 25
1.0%
6.5%
Q1 25
-3.6%
-6.6%
Q4 24
9.9%
-0.5%
Q3 24
15.0%
16.2%
Q2 24
12.5%
7.9%
Capex Intensity
CLOV
CLOV
SXT
SXT
Q1 26
Q4 25
0.4%
8.0%
Q3 25
0.1%
4.8%
Q2 25
0.1%
5.1%
Q1 25
0.0%
4.3%
Q4 24
0.5%
6.1%
Q3 24
0.1%
3.4%
Q2 24
0.1%
2.9%
Cash Conversion
CLOV
CLOV
SXT
SXT
Q1 26
Q4 25
1.75×
Q3 25
1.19×
Q2 25
1.28×
Q1 25
-0.26×
Q4 24
0.71×
Q3 24
2.35×
Q2 24
6.04×
1.42×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons